10.20
+0.36(+3.66%)
Currency In USD
| Previous Close | 9.84 |
| Open | 9.88 |
| Day High | 10.83 |
| Day Low | 9.39 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 112,411 |
| Average Volume | 96,809 |
| Market Cap | 62.74M |
| PE | -0.77 |
| EPS | -13.27 |
| Moving Average 50 Days | 8.18 |
| Moving Average 200 Days | 15.23 |
| Change | 0.36 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $27.47 as of August 24, 2025 at a share price of $10.2. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $289.36 as of August 24, 2025 at a share price of $10.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
GlobeNewswire Inc.
Aug 20, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
GlobeNewswire Inc.
Aug 13, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, toda